24 May 2013, BioSpectrum Bureau , BioSpectrum
Singapore: Macrocyclics, an Areva Med company, entered into a new collaborative research agreement with Roche for the continued development of novel chelating agents designed specifically by Macrocyclics for Roche's applications. This will be the second collaboration between the two firms after the successful completion of their first 2012 venture.
The new project will build on the already established expertise related to lead-212 (212Pb) and novel chelate architecture for radioimmunotherapy. The high level of synergy between the two firms is expected to speed up the clinical development process.
Mr Garry Kiefer , CEO, Macrocyclics, said that, "We are privileged to be working with the world leader in oncology and antibody technology and are excited to contribute in the development of powerful new therapies based on lead-212."